Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGaming Realms Regulatory News (GMR)

Share Price Information for Gaming Realms (GMR)

Share Price is delayed by 15 minutes
Get Live Data
30.80    -0.60 (-1.91%)
Bid:
30.00
Ask:
30.80
Spread: 0.80 (2.667%)
Market Cap: £83.88m
GMR Live PriceLast checked at - London Stock Exchange

Intraday Gaming Realms Share Chart

Agreements signed with KFT

13 Apr 2011 07:39

RNS Number : 8173E
Pursuit Dynamics PLC
13 April 2011
 



13 April 2011

 

Pursuit Dynamics PLC ("PDX" or "the Company")

 

Development and distribution agreements signed with Kaercher Futuretech GmbH ("KFT")

PDX is pleased to announce that it has signed development and distribution agreements with KFT to structure the commercial cooperation between the companies that was first announced in April last year. PDX has formed a dedicated subsidiary, DDX Solutions AG, through which it will work with KFT to deliver a series of innovative products starting this calendar year.

 

KFT, a wholly owned subsidiary of Alfred Kaercher GmbH, the world's leading manufacturer of high-pressure cleaning and disinfectant equipment will, together with PDX, jointly develop, produce and market civilian and military decontamination and disinfection products for the global market. The cooperation combines KFT's experience as a world leader in decontamination solutions and its core competencies in manufacturing, distribution and after sales support, with PDX's best in class technology to form a new product range focused on quality, mobility and efficiency.

 

The relationship between KFT and PDX has been established by two multi product contracts - a development agreement and a distribution agreement - that create clear lines of responsibility and accountability. The structure affords PDX ownership of the products as well as control over design and development. KFT will manage manufacturing orders, inventory and spare parts. KFT will also be responsible for marketing and distribution and will also bear all marketing and distribution costs.

 

In addition, as part of the agreement, KFT will guarantee a minimum sales threshold to be agreed each year to maintain its right to distribute the jointly developed products.

 

Under the agreements, PDX will be entitled to receive a margin on all sales of equipment, parts and chemical products.

 

The first product to go to market will be the First Responder System, utilising PDX's atomisation technology. Prototype testing of both the backpack and trolley models is well under way with mass manufacture expected to begin in Q3 of this calendar year. Sales pipeline development will begin shortly thereafter with the first product shipments due in Q4 of this calendar year. The initial feedback from premarketing has been encouraging, with a number of major organisations expressing high levels of interest.

 

KFT and PDX are also developing a hospital mobile decontamination product, the development of which has been accelerated due to positive market feedback. PDX expects a further three product lines to be delivered later this year and through 2012. Further details will be provided in due course.

 

Roel Pieper, CEO of PDX, commented:

 

"With this agreement PDX is now extremely well placed to drive significant commercial returns from the multi-billion dollar global mobile decontamination market. The agreements with KFT give us a competitive product offering in the global chemical and biological decontamination markets, whilst NDX, PDX's joint venture with the UK's National Nuclear Laboratories, positions us in the nuclear decontamination market as well. I am extremely excited by this business and I am looking forward to a long and fruitful cooperation with KFT."

 

Hagen Gehringer, Managing Director of KFT, commented:

 

"PDX's unique technology enables us to bring to market state of the art products and create best in class applications. With their innovation and our experience and know-how we have formed a formidable partnership. We are excited by the significant opportunities that we are addressing." 

 

- Ends -

 

 

For Further Information, please contact:

 

PDX

Roel Pieper, CEO

Tel: +44 (0)1480 422050

Richard Webster, CFO

Financial Dynamics

Ben Foster

Marc Cohen

Tel: +44 (0) 20 7831 3113

 

Cenkos Securities

Ian Soanes

Max Hartley

Tel: +44 (0)20 7397 8924

Mirabaud Securities

Rory Scott

Tel: +44 (0) 20 7878 3360

 

Notes to Editors

 

About PDX

 

- PDX (AIM: PDX) owns and commercialises the PDX Atomiser and Reactor

technologies that enable significant reductions in energy usage, process acceleration and result enhancement for a wide range of industrial processes and applications.

 

- The PDX business model is currently organised into five Lines of Business

Biofuels; Brewing, Food and Beverages; Public Health and Decontamination

Industrial Licensing; Water.

 

- PDX is headquartered in Huntingdon (UK) with an office in London (UK),

Schaffhausen (Switzerland) and Connecticut (USA).

 

- Further information is available at the Company's website: www.pdx.biz 

 

- Publication quality photographs are available from FD.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRGLGDSRXBBGBX
Date   Source Headline
1st Aug 20111:41 pmRNSExercise of Options
29th Jul 20117:00 amRNSFuture Biogas Trial
27th Jul 20111:32 pmRNSExercise of Options
20th Jul 20117:00 amRNSJoint Venture with Biomimetics
14th Jul 201112:34 pmRNSHolding(s) in Company
12th Jul 201112:33 pmRNSExercise of Options
28th Jun 201112:04 pmRNSHolding(s) in Company
28th Jun 201111:59 amRNSHolding(s) in Company
28th Jun 20117:00 amRNSExercise of Options
23rd Jun 20117:00 amRNSExercise of Options
22nd Jun 20117:00 amRNS3 new biofuel plants signed
20th Jun 20112:32 pmRNSHolding(s) in Company
14th Jun 20117:00 amRNSBrewing Agreement
14th Jun 20117:00 amRNSBoard Changes
14th Jun 20117:00 amRNSInterim Results
25th May 20117:05 amRNSHolding(s) in Company
25th May 20117:00 amRNSNew Biofuels Agreement
6th May 20119:58 amRNSNotice of Results
28th Apr 20112:48 pmRNSTotal Voting Rights
21st Apr 20115:26 pmRNSHolding(s) in Company
20th Apr 20114:10 pmRNSProposed Placing
13th Apr 20117:39 amRNSAgreements signed with KFT
30th Mar 20115:37 pmRNSAnnual Report and Accounts
28th Mar 20112:25 pmRNSHolding(s) in Company
18th Mar 20117:06 amRNSBiofuels Update
3rd Mar 20112:11 pmRNSExercise of Options
28th Feb 20112:33 pmRNSResult of AGM
28th Feb 20117:00 amRNSAGM Statement
9th Feb 20117:00 amRNSBiofuels Update
7th Feb 20111:26 pmRNSDirector's Dealings
4th Feb 20114:15 pmRNSHolding(s) in Company
3rd Feb 20117:00 amRNSUpdate on JV with NNL
2nd Feb 20113:46 pmRNSExercise of Options
20th Jan 20115:03 pmRNSStatement re share price
12th Jan 20117:00 amRNSBiofuels Update
15th Dec 201012:34 pmRNSDirector/PDMR Shareholding
9th Dec 20104:47 pmRNSHolding(s) in Company
7th Dec 201012:10 pmRNSOptions and Directors Dealings
7th Dec 201012:05 pmRNSHolding(s) in Company
3rd Dec 20107:00 amRNSFinal Results
22nd Nov 20107:00 amRNSBio-fuels update
16th Nov 20103:16 pmRNSHolding(s) in Company
15th Nov 20103:58 pmRNSHolding(s) in Company
8th Nov 20104:08 pmRNSNotice of Results
5th Nov 20109:39 amRNSAgreement with P&G
14th Oct 201012:52 pmRNSEthanol Blendwall Increase
6th Oct 20107:00 amRNSDirectorate Change
30th Sep 20107:00 amRNSExercise of Options
16th Sep 20107:00 amRNSDecon JV Agreement
7th Sep 201010:59 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.